Allen Nissenson
CIK 1441889 · Chief Medical Officer · last filed 2026-09-02
Allen Nissenson is a Chief Medical Officer who has filed 33 SEC Form 4 insider transactions across 4 companies since 2008. The most recent filing, for ELTX, was dated Sep 2, 2026. Across all open-market trades the lifetime net is −$2.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions. 19 SEC filings were submitted jointly with DAVITA INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DVA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
EL SEGUNDO, CA 90245
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELTX | Director | — | $1.70 | — | $0 | 4 | 2026-09-02 |
| RMTI | Director | 23,892 | $7.00 | $167.2K | $0 | 8 | 2026-07-06 |
| Elicio Therapeutics, Inc. (ANGN) Delisted | Director | 938 | $10.00 | $9.4K | $10.9K | 3 | 2022-06-13 |
| DVA | Chief Medical Officer | 8,990 | $184.03 | $1.65M | -$2.79M | 18 | 2014-02-18 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-02 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2026-07-06 | RMTI | Grant (A) | +9,633 | $0 | EDGAR |
| 2025-05-21 | RMTI | Grant (A) | +50,000 | $0 | EDGAR |
| 2025-05-20 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2024-11-25 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2024-05-23 | RMTI | Grant (A) | +36,111 | $0 | EDGAR |
| 2023-12-29 | ELTX | Grant (A) | — | $0 | EDGAR |
| 2023-05-25 | RMTI | Grant (A) | +24,715 | $0 | EDGAR |
| 2022-06-13 | Elicio Therapeutics, Inc. (ANGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | RMTI | Grant (A) | +25,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.